Procter & Gamble Health to Consider Q1 FY26 Results on August 1; Q4 FY25 PAT Falls 33% YoY
By Ankur Chandra | Published at: Jun 27, 2025 03:21 PM IST
Mumbai, June 27: Procter & Gamble Health Ltd (NSE: PGHL) has scheduled its next board meeting on August 1, 2025, to consider and approve the unaudited standalone financial results for the quarter ended June 30, 2025 (Q1 FY26).
Procter & Gamble Health reported lower profitability for the quarter ended March 31, 2025, despite steady revenue growth. While net profit rose year-on-year, a high Q3 base led to a sharp sequential decline. Q1 FY26 results will offer the first glimpse into the company’s FY26 trajectory.
The company disclosed this to the exchanges under Regulation 29(1)(a) of SEBI LODR. Furthermore, per SEBI’s insider trading rules, the trading window of the company will be closed from July 1, 2025. It will reopen on August 4, 2025, 48 hours after the disclosure of financial results.
Shares of Procter & Gamble Health Ltd opened in green at ₹5,874.00 and rose to ₹5,925.00 by 1:39 PM today, registering a 1.19% intraday gain.
Q4 FY25 (Mar 2025) Results – YoY and QoQ Snapshot
Procter & Gamble Health reported a decline in profitability for the quarter ended March 31, 2025, even as revenue remained strong.
| Particulars | Q4 FY25 (Mar ’25) | Q4 FY24 (Mar ’24) | YoY Change | Q3 FY25 (Dec ’24) | QoQ Change |
|---|---|---|---|---|---|
| Total Income (₹ Cr) | 3,141.00 | 2,547.50 | ▲ 23.3% | 3,137.30 | ▲ 0.1% |
| Profit Before Tax (₹ Cr) | 785.30 | 627.20 | ▲ 25.2% | 1,216.90 | ▼ 35.5% |
| Net Profit (₹ Cr) | 611.80 | 465.60 | ▲ 31.4% | 909.00 | ▼ 32.7% |
| EPS (₹) | 36.86 | 28.00 | ▲ 31.6% | 54.76 | ▼ 32.7% |
Despite a year-on-year surge in net profit, the company faced a significant decline on a sequential basis, largely due to a high base in Q3.
Quarterly Trend – Last 5 Quarters
| Quarter Ended | Total Income (₹ Cr) | PBT (₹ Cr) | Net Profit (₹ Cr) | EPS (₹) | Remarks |
|---|---|---|---|---|---|
| Mar ’25 | 3,141.00 | 785.30 | 611.80 | 36.86 | Audited |
| Dec ’24 | 3,137.30 | 1,216.90 | 909.00 | 54.76 | Un-Audited |
| Sep ’24 | 3,166.90 | 1,114.00 | 823.30 | 49.60 | Un-Audited |
| Jun ’24 | 2,860.10 | 228.30 | 167.80 | 10.11 | Audited |
| Mar ’24 | 2,547.50 | 627.20 | 465.60 | 28.00 | Un-Audited |
Trading Window Status
| Event | Date |
|---|---|
| Start of Trading Window Closure | July 1, 2025 |
| End of Trading Window Closure | August 3, 2025 |
The earnings for Q1 FY26 will be the first indication of the company’s performance in the new fiscal year. With revenue growth seen across FY25, the market will be closely watching profit margin resilience and potential management commentary on input cost trends or healthcare demand outlook.
Outlook
The upcoming board meeting will set the tone for the FY26 performance evaluation. While prior quarters showed mixed profitability, investor sentiment remains cautiously optimistic. Markets will watch for margin trends, cost pressures, and early signals on healthcare demand to guide near-term stock movement.
REF: https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_58492_1472820_27062025010047_WEB.xml
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
